Delivering the Precision Oncology Paradigm

Key findings

• List itemPrecision medicine drugs cost $1bn less to develop than traditional drugs, mainly due to smaller clinical trials and the accelerated path to the market
• Historically precision medicine sales have averaged $5.2bn over the lifetime of the drug, considerably less than non-precision medicine oncology therapies
• The authors note that the precision medicine revenues are significantly constrained because of inefficiencies in the diagnostic pathway denying the drugs access to 64% of potentially eligible patients 

• Recommendations include moving towards a precision oncology CDx-guided approach which can deliver health benefits at a potentially affordable cost, including in the development phase, lowering expensive clinical trial attrition rates, and sparing unselected patients those treatments that are ineffective and may have significant side effects